Christian Angermayer is a venture capital investor at Presight Capital who focuses specifically on psychedelics, longevity, space, and AI technologies that he believes can extend healthy life and improve happiness. He openly credits his own psychedelic experience as the catalyst for shifting his investment focus toward building an entire psychedelic medicines ecosystem, making him an unusually visible pioneer in establishing medical psychedelics as an institutional asset class.

• Deep conviction in the medical potential of psychedelics to solve the global mental health crisis. He frequently highlights progress made by his portfolio company Atai Life Sciences, specifically celebrating milestones like FDA breakthrough designations or successful trial data for compounds involving MDMA and 5-MeO-DMT.
• Championing the intersection of sports and medical science through the Enhanced Games. He actively promotes this venture as a way to safely embrace performance enhancements and push human limits, recently utilizing the recruitment of strongman Thor Bjornsson to generate excitement for the upcoming event in Las Vegas.
• Bullish outlook on the convergence of future technologies, specifically highlighting the combination of generative AI with robotics and the mass adoption of stablecoins. He views stablecoins as a major strategic priority for governments and corporations by 2026 and sees AI infrastructure as a driver for an unprecedented economic boom.
• Strategic focus on critical minerals and natural resources required to support future infrastructure. He has identified a looming global supply deficit in copper expected by 2040 and promotes investments in new mining discoveries to capitalize on these long-term macro trends.
• Strong preference for the United States as the primary hub for innovation and business growth compared to Europe. He has been vocal about redomiciling his companies to the US to access major equity indices and capital markets, urging European leaders to wake up to their waning competitiveness.